SynthesisQJM : monthly journal of the Association of Physicians2013
Direct-acting antiviral therapies for hepatitis C genotype 1 infection: a multiple treatment comparison meta-analysis.
Synthesis in QJM : monthly journal of the Association of Physicians, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 3 syntheses or guidelines pooled it, 40 citations in OpenAlex.
- Network meta-analysis of first- and second-generation protease inhibitors for chronic hepatitis C genotype 1: efficacy based on RVR and SVR 24.European journal of clinical pharmacology · 2017Pooled it
- Pooled it
- Testing for HCV infection: an update of guidance for clinicians and laboratorians.MMWR. Morbidity and mortality weekly report · 2013Guideline
- Human single chain-transbodies that bound to domain-I of non-structural protein 5A (NS5A) of hepatitis C virus.Scientific reports · 2017Article
- The state of gene therapy research in Africa, its significance and implications for the future.Gene therapy · 2017Review
- Does Hepatitis C Treatment Adherence Affect Risk of Liver Transplantation? A Historical Cohort Study.Journal of managed care & specialty pharmacy · 2016Observational
- Hepatitis C virus and non-Hodgkin's lymphomas: Meta-analysis of epidemiology data and therapy options.World journal of hepatology · 2016Review
- Human Transbodies to HCV NS3/4A Protease Inhibit Viral Replication and Restore Host Innate Immunity.Frontiers in immunology · 2016Article
- Health state utilities associated with attributes of treatments for hepatitis C.The European journal of health economics : HEPAC : health economics in prevention and care · 2015Article
- Impact of all oral anti-hepatitis C virus therapy: A meta-analysis.World journal of hepatology · 2015Article
- Computational Docking Study of p7 Ion Channel from HCV Genotype 3 and Genotype 4 and Its Interaction with Natural Compounds.PloS one · 2015Article
- Article
- New triple therapy for chronic hepatitis C: real life clinical experience in a community setting.Hawai'i journal of medicine & public health : a journal of Asia Pacific Medicine & Public Health · 2013Article
- Management algorithm for genotype 1 hepatitis C virus.F1000prime reports · 2013Article
- Interpreting discordant indirect and multiple treatment comparison meta-analyses: an evaluation of direct acting antivirals for chronic hepatitis C infection.Clinical epidemiology · 2013Article
- Budget impact analysis of boceprevir and telaprevir for the treatment of hepatitis C genotype 1 infection.ClinicoEconomics and outcomes research : CEOR · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNew direct-acting antiviral agents for hepatitis C genotype 1 infection, boceprevir and telaprevir, offer enhanced sustained virologic response (SVR) among both treatment-naïve and treatment-experienced patients.
aimTo determine the relative efficacy of the new direct-acting antiviral agents by applying a multiple treatment comparison meta-analysis.
designWe included published Phase II and III randomized controlled trials evaluating head-to-head comparisons between boceprevir, telaprevir, peg-interferon alpha-2a with ribavirin and peg-interferon alpha-2b with ribavirin in hepatitis C genotype 1 patients. We applied Bayesian multiple treatment comparison meta-analysis.
resultsWe included data from four boceprevir, three telaprevir and six peg-interferon alpha-2a plus ribavirin vs. peg-interferon alpha-2b plus ribavirin randomized controlled trials. Both boceprevir and telaprevir offer statistically superior outcomes for SVR, relapse and discontinuation due to adverse events than either peg-interferons among both treatment-naïve and treatment-experienced patients. Among treatment-naïve patients, clinical outcomes were similar for boceprevir and telaprevir, for SVR [odds ratio (OR) 0.90, 95% credible interval (95% CrI) 0.41-1.91] and for relapse (OR 1.09, 95% CrI 0.19-4.84). Similarly, among treatment-experienced patients, clinical outcomes were similar for boceprevir and telaprevir and for SVR (OR 1.45, 95% CrI 0.70-3.08) and for relapse (OR 0.35, 95% CrI 0.13-1.02). For treatment-naïve patients receiving standard-duration therapy, telaprevir yielded lower rates of anemia and neutropenia, but higher rates of rash and pruritus. For treatment-experience patients, all adverse event rates were higher with telaprevir. DISCUSSION: Boceprevir and telaprevir exhibit similar effects among hepatitis C genotype 1 treatment-naïve and treatment-experienced patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.